Mapping of C5 ‐Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition
Immunology · 2026
DOI: 10.1111/imm.70180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2026. Verfasst von Rebekah Sian Cooke und 5 weiteren Autor:innen. Beteiligte Einrichtung: UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK. Hauptthemen laut MEDLINE: Complement C5, Antibodies, Monoclonal, Epitope Mapping, Epitopes. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation, UK Dementia Research Institute, CSP VA.
Abstract (Originalsprache)
C5 inhibition is a proven therapeutic target with several monoclonal antibody (mAb) and small molecule drugs in the clinic. To explore alternative modes of inhibition, novel C5‐blocking mAbs were generated and compared to therapeutic mAbs eculizumab and crovalimab. Blocking mAbs were selected using complement inhibition in haemolysis assays. C5 binding and competition between mAbs were tested by ELISA and surface plasmon resonance. Impact on C5 cleavage by CVF and native convertases was tested by western blotting of C5 fragments and ELISA for C5a release. Four novel C5‐blocking mAbs were identified and shown to inhibit haemolysis with comparable efficacy to crovalimab and eculizumab. Competition assays identified four distinct function‐blocking epitopes; mAb 7D4 and eculizumab competed for an α‐chain epitope (epitope 1), while 10B6 and crovalimab competed for a β‐chain epitope (epitope 2). mAbs 2B11 and 4G2 were not competitive with epitope 1/2 binders or each other, marking two distinct blocking α‐chain epitopes (epitopes 3 and 4). Epitope 1 and epitope 2 binders blocked C5 convertase‐mediated C5 cleavage and C5a release, while epitope 3 and epitope 4 binders permitted C5 cleavage, demonstrating distinct modes of inhibition. We identified four distinct C5 blocking epitopes; epitope 1 targeted by eculizumab and 7D4, epitope 2 targeted by crovalimab and 10B6 and epitopes 3 and 4 targeted by 2B11 and 4G2 respectively. Although all efficiently blocked haemolysis, epitope 3 and 4 binders permitted C5a release. We reveal (at least) four blocking epitopes on C5 and (at least) two distinct mechanisms of inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
- Molecular Biosciences Division, School of Biosciences, Cardiff University, Cardiff, UK.
- Department of Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
ORCID-Profile: Rebekah Sian Cooke, Kok Yung Lee, Georgina Elizabeth Menzies, Bryan Paul Morgan, Wioleta Milena Zelek
Förderung
- UK Research and Innovation
- UK Dementia Research Institute
- CSP VA
- Alzheimers Society
Zitieren
APA
Cooke, R. S., Lee, K. Y., Menzies, G. E., Mizuno, M., Morgan, B. P., & Zelek, W. M. (2026). Mapping of C5 ‐Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition. Immunology. https://doi.org/10.1111/imm.70180
Vancouver
Cooke RS, Lee KY, Menzies GE, Mizuno M, Morgan BP, Zelek WM. Mapping of C5 ‐Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition. Immunology. 2026. doi:10.1111/imm.70180
BibTeX
@article{Cooke2026,
author = {Cooke, Rebekah Sian and Lee, Kok Yung and Menzies, Georgina Elizabeth and Mizuno, Masashi and Morgan, Bryan Paul and Zelek, Wioleta Milena},
title = {Mapping of C5 ‐Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition},
journal = {Immunology},
year = {2026},
doi = {10.1111/imm.70180}
}
EUVIMED